Education
About Us
Working with TipRanks
Follow Us
Transgene SA (FR:TNG)
:TNG
TNG Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.53 - €1.21
Previous CloseN/A
Volume15.92K
Average Volume (3M)103.77K
Market Cap
€135.04M
Enterprise Value€83.28M
Total Cash (Recent Filing)€16.67M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Sep 16, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding132,735,080
10 Day Avg. Volume133,629
30 Day Avg. Volume103,771
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.53 and its highest was €1.21 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €135.04M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 16, 2025 which is in 27 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 132,735,080 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
Company Description
Transgene SA
Transgene (TNG) is a biotechnology company specializing in the design and development of immunotherapeutic products to treat cancer and infectious diseases. The company's core products include therapeutic vaccines and oncolytic viruses, which are aimed at stimulating the body's immune system to target and destroy diseased cells. Transgene operates primarily in the biotechnology and pharmaceutical sectors, leveraging cutting-edge research and development to bring innovative therapies to market.